Terms: = Breast cancer AND MYC, c-Myc, 4609, ENSG00000136997
2700 results:
1. Loss of tumor-derived SMAD4 enhances primary tumor growth but not metastasis following BMP4 signalling.
Chi LH; Redfern AD; Roslan S; Street IP; Burrows AD; Anderson RL
Cell Commun Signal; 2024 Apr; 22(1):248. PubMed ID: 38689334
[TBL] [Abstract] [Full Text] [Related]
2. Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors.
Gupta V; Vashisht V; Vashisht A; Mondal AK; Alptekin A; Singh H; Kolhe R
Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674331
[TBL] [Abstract] [Full Text] [Related]
3. Interleukin 33 supports squamous cell carcinoma growth via a dual effect on tumour proliferation, migration and invasion, and T cell activation.
Perri G; Vilas Boas VG; Nogueira MRS; Mello Júnior EJF; Coelho AL; Posadas EM; Hogaboam C; Cavassani KA; Campanelli AP
Cancer Immunol Immunother; 2024 Apr; 73(6):110. PubMed ID: 38662248
[TBL] [Abstract] [Full Text] [Related]
4. Deciphering the molecular biology of inflammatory breast cancer through molecular characterization of patient samples and preclinical models.
Rypens C; Van Berckelaer C; Berditchevski F; van Dam P; Van Laere S
Int Rev Cell Mol Biol; 2024; 384():77-112. PubMed ID: 38637101
[TBL] [Abstract] [Full Text] [Related]
5. The myc-associated zinc finger protein epigenetically controls expression of interferon-γ-stimulated genes by recruiting STAT1 to chromatin.
Xiao T; Li X; Felsenfeld G
Proc Natl Acad Sci U S A; 2024 Apr; 121(17):e2320938121. PubMed ID: 38635637
[TBL] [Abstract] [Full Text] [Related]
6. Unveiling the Mechanism of the ChaiShao Shugan Formula Against Triple-Negative breast cancer.
Fan T; Huang Y; Liu Z; Huang J; Ke B; Rong Y; Qiu H; Zhang B
Drug Des Devel Ther; 2024; 18():1115-1131. PubMed ID: 38618280
[TBL] [Abstract] [Full Text] [Related]
7. Structure-Guided Discovery and Preclinical Assessment of Novel (Thiophen-3-yl)aminopyrimidine Derivatives as Potent ERK1/2 Inhibitors.
Shuai W; Xiao H; Yang P; Zhang Y; Bu F; Wu Y; Sun Q; Wang G; Ouyang L
J Med Chem; 2024 Apr; 67(8):6425-6455. PubMed ID: 38613499
[TBL] [Abstract] [Full Text] [Related]
8. U2AF2-SNORA68 promotes triple-negative breast cancer stemness through the translocation of RPL23 from nucleoplasm to nucleolus and c-myc expression.
Zhang W; Song X; Jin Z; Zhang Y; Li S; Jin F; Zheng A
Breast Cancer Res; 2024 Apr; 26(1):60. PubMed ID: 38594783
[TBL] [Abstract] [Full Text] [Related]
9. Genetic interactions reveal distinct biological and therapeutic implications in breast cancer.
Lin CJ; Jin X; Ma D; Chen C; Ou-Yang Y; Pei YC; Zhou CZ; Qu FL; Wang YJ; Liu CL; Fan L; Hu X; Shao ZM; Jiang YZ
Cancer Cell; 2024 Apr; 42(4):701-719.e12. PubMed ID: 38593782
[TBL] [Abstract] [Full Text] [Related]
10. Development, synthesis and validation of improved c-myc/Max inhibitors.
Yıldırım S; Kocabaş F; Mermer A
J Cell Mol Med; 2024 Apr; 28(8):e18272. PubMed ID: 38568057
[TBL] [Abstract] [Full Text] [Related]
11. Bone Endosteal Mimics Regulates breast cancer Development and Phenotype.
Ben Ghedalia Peled N; Hoffman DK; Barsky L; Zer NS; Amar K; Rapaport H; Gheber LA; Zhang XH; Vago R
Biomacromolecules; 2024 Apr; 25(4):2338-2347. PubMed ID: 38499995
[TBL] [Abstract] [Full Text] [Related]
12. Characterization of MYBL1 Gene in Triple-Negative breast cancers and the Genes' Relationship to Alterations Identified at the Chromosome 8q Loci.
Player A; Cunningham S; Philio D; Roy R; Haynes C; Dixon C; Thirston L; Ibikunle F; Boswell TA; Alnakhalah A; Contreras J; Bell M; McGuffery T; Bryant S; Nganya C; Kanu S
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473786
[TBL] [Abstract] [Full Text] [Related]
13. MicroRNA-561-3p indirectly regulates the PD-L1 expression by targeting ZEB1, HIF1A, and myc genes in breast cancer.
Yousefi A; Sotoodehnejadnematalahi F; Nafissi N; Zeinali S; Azizi M
Sci Rep; 2024 Mar; 14(1):5845. PubMed ID: 38462658
[TBL] [Abstract] [Full Text] [Related]
14. Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions.
Gerosa R; De Sanctis R; Jacobs F; Benvenuti C; Gaudio M; Saltalamacchia G; Torrisi R; Masci G; Miggiano C; Agustoni F; Pedrazzoli P; Santoro A; Zambelli A
Crit Rev Oncol Hematol; 2024 Apr; 196():104324. PubMed ID: 38462150
[TBL] [Abstract] [Full Text] [Related]
15. Altered hormone expression induced genetic changes leads to breast cancer.
Thakur A; Rana N; Kumar R
Curr Opin Oncol; 2024 Mar; 36(2):115-122. PubMed ID: 38441060
[TBL] [Abstract] [Full Text] [Related]
16. Cytoplasmic localization of SETDB1‑induced Warburg effect via c‑myc‑LDHA axis enhances migration and invasion in breast carcinoma.
Yang W; Wei Y; Wang T; Xu Y; Jin X; Qian H; Yang S; He S
Int J Mol Med; 2024 Apr; 53(4):. PubMed ID: 38426579
[TBL] [Abstract] [Full Text] [Related]
17. myc induces CDK4/6 inhibitors resistance by promoting pRB1 degradation.
Ma J; Li L; Ma B; Liu T; Wang Z; Ye Q; Peng Y; Wang B; Chen Y; Xu S; Wang K; Dang F; Wang X; Zeng Z; Jian Y; Ren Z; Fan Y; Li X; Liu J; Gao Y; Wei W; Li L
Nat Commun; 2024 Feb; 15(1):1871. PubMed ID: 38424044
[TBL] [Abstract] [Full Text] [Related]
18. MicroRNA-203a inhibits breast cancer progression through the PI3K/Akt and Wnt pathways.
Entezari M; Soltani BM; Sadeghizadeh M
Sci Rep; 2024 Feb; 14(1):4715. PubMed ID: 38413784
[TBL] [Abstract] [Full Text] [Related]
19. scCircle-seq unveils the diversity and complexity of extrachromosomal circular DNAs in single cells.
Chen JP; Diekmann C; Wu H; Chen C; Della Chiara G; Berrino E; Georgiadis KL; Bouwman BAM; Virdi M; Harbers L; Bellomo SE; Marchiò C; Bienko M; Crosetto N
Nat Commun; 2024 Feb; 15(1):1768. PubMed ID: 38409079
[TBL] [Abstract] [Full Text] [Related]
20. Selective CDK7 Inhibition Suppresses Cell Cycle Progression and myc Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive breast cancer.
Guarducci C; Nardone A; Russo D; Nagy Z; Heraud C; Grinshpun A; Zhang Q; Freelander A; Leventhal MJ; Feit A; Cohen Feit G; Feiglin A; Liu W; Hermida-Prado F; Kesten N; Ma W; De Angelis C; Morlando A; O'Donnell M; Naumenko S; Huang S; Nguyen QD; Huang Y; Malorni L; Bergholz JS; Zhao JJ; Fraenkel E; Lim E; Schiff R; Shapiro GI; Jeselsohn R
Clin Cancer Res; 2024 May; 30(9):1889-1905. PubMed ID: 38381406
[TBL] [Abstract] [Full Text] [Related]
[Next]
